Skip to main content

Table 4 Treatments of bone DLBCL

From: Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas

Parameter Number (%)  
uPB-DLBCL mPB-DLBCL SB-DLBCL*
Treatment n = 37 n = 23 n = 12
CMT 11(29.7) 16(69.6) 7(58.3)
RT 1(2.7) 0 0
CMT and RT 24(54.1) 6(26.1) 5(41.7)
No CMT or RT 1(2.7) 1(4.3) 0
Chemotherapy n = 35 n = 22 n = 12
CHOP or CHOP-like CHOP-like 7(20.0) 0 1(8.3%)
CHOP + rituximab 28(80.0) 22(100.0) 11(91.7%)
  1. Abbreviations uPB-DLBCL: primary bone diffuse large B-cell lymphoma with unifocal bone disease; mPB-DLBCL: primary bone diffuse large B-cell lymphoma with multifocal bone disease; SB-DLBCL: secondary bone diffuse large B-cell lymphoma; CMT: chemotherapy; RT: radiation therapy.
  2. *SB-DLBCL with recurrent bone involvement was not included in the table.